Consolidated Financial Statements June 30, 2025 and 2024



### **Report of Independent Auditors**

To The Trustees of Columbia University in the City of New York

### **Opinion**

We have audited the accompanying consolidated financial statements of The Trustees of Columbia University in the City of New York and its subsidiaries (the "University"), which comprise the consolidated statements of financial position as of June 30, 2025 and 2024, and the related consolidated statements of activities for the year ended June 30, 2025 and of cash flows for the years ended June 30, 2025 and 2024, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the University as of June 30, 2025 and 2024, the changes in its net assets for the year ended June 30, 2025, and its cash flows for the years ended June 30, 2025 and 2024 in accordance with accounting principles generally accepted in the United States of America.

## **Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Other Matter

We previously audited the consolidated statement of financial position as of June 30, 2024, and the related consolidated statements of activities and of cash flows for the year then ended (the statement of activities is not presented herein), and in our report dated September 27, 2024, we expressed an unmodified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying summarized financial information as of June 30, 2024 and for the year then ended is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

### Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements were issued.

### Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute



assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

## Other Information

Management is responsible for the other information included in the annual report. The other information comprises the Columbia University Financial Overview For The Year 2024-2025, but does not include the consolidated financial statements and our auditor's report thereon. Our opinion on the consolidated financial statements does not cover the other information, and we do not express an opinion or any form of assurance thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and consider whether a material inconsistency exists between the other information and the consolidated financial statements or the other information otherwise appears to be materially misstated. If, based on the work performed, we conclude that an uncorrected material misstatement of the other information exists, we are required to describe it in our report.

New York, New York October 23, 2025

Pricewaterhouse Coopers LLP

# The Trustees of Columbia University in the City of New York Consolidated Statements of Financial Position

At June 30, 2025 and 2024

(in thousands of dollars)

	June 2025	June 2024
Assets		
Cash and cash equivalents	\$1,145,338	\$974,557
Accounts receivable, net	1,058,912	805,204
Securities held in trust by others	615	589
Pledges receivable, net	565,308	533,888
Investments, at fair value	16,454,027	15,722,372
Institutional real estate	1,245,213	1,213,213
Land, buildings, and equipment, net	4,876,382	4,875,864
Right of use, lease assets	257,879	254,355
Other assets	458,763	455,889
Total assets	\$26,062,437	\$24,835,931
Liabilities		
Accounts payable and accrued expenses	\$525,283	\$508,922
Deferred revenue and other prepayments	375,372	369,765
Finance lease obligations	134,910	131,190
Right of use, lease obligations	271,231	266,319
Conditional asset retirement obligations	144,784	138,572
Accrued employee benefit liabilities	630,821	562,258
Federal student loan funds	20,775	23,593
Bonds and notes payable (net of bond premium and issuance costs	20,773	25,595
of \$250,329 and \$253,136) (see Note 15)	2,786,770	2,249,564
Other long-term liabilities	654,789	791,449
Total liabilities	5,544,735	5,041,632
Net assets		
Without donor restrictions	8,289,023	8,502,576
With donor restrictions	12,228,679	11,291,723
Total net assets	20,517,702	19,794,299
Total liabilities and net assets	\$26,062,437	\$24,835,931

See accompanying notes to the consolidated financial statements.

# The Trustees of Columbia University in the City of New York Consolidated Statements of Activities

For the Year Ended June 30, 2025, with Summarized Comparative 2024 Totals (in thousands of dollars)

	Without Donor Restrictions	With Donor Restrictions	June 2025	June 2024
Operating activities				-
Revenues and support				
Tuition and fees (net of \$622,628 and \$595,033				
in financial aid grants, respectively)	\$1,577,424		\$1,577,424	\$1,514,596
Government grants and contracts	1,313,663		1,313,663	1,329,009
Private gifts, grants and contracts	378,616	211,188	589,804	653,56
Revenue from other educational and	,	,	/	,
research activities	251,788		251,788	259,71
Patient care revenue	1,896,816		1,896,816	1,783,69
Investment income and gains utilized	578,060	285,031	863,091	815,78
Sales and services of auxiliary enterprises	252,393	,	252,393	247,35
Net assets released from restrictions	457,736	(457,736)		- ,
Total operating revenues and support	6,706,496	38,483	6,744,979	6,603,72
Expenses				
Instruction and educational administration	2,462,900		2,462,900	2,415,56
Research	988,703		988,703	951,34
Patient care expense	1,682,558		1,682,558	1,555,43
Operation and maintenance of plant	404,668		404,668	367,00
Institutional support	459,343		459,343	386,28
Auxiliary enterprises	232,272		232,272	228,33
Depreciation Depreciation	322,573		322,573	327,63
Interest	79,363		79,363	67,32
Total expenses	6,632,380		6,632,380	6,298,91
Change in net assets from operating activities	74,116	38,483	112,599	304,81
Nonoperating activities				
Endowment gifts		177,866	177,866	237,24
Current year realized and unrealized capital		177,000	177,000	237,21
gains	530,057	1,147,549	1,677,606	1,491,66
Endowment appreciation utilized	(234,288)	(487,071)	(721,359)	(694,25
Change in net assets held by CPMC Fund, Inc.	(23 1,200)	942	942	58
Change in funds held by others in perpetuity		15,313	15,313	19,72
Present value adjustment to split-interest agreements	7,447	16,518	23,965	25,84
Net periodic benefit cost other than service cost	4,099	10,510	4,099	10,07
Changes in pension and postretirement obligations	(16,772)		(16,772)	(10,00
Other	(550,856)		(550,856)	(309,21
Reclassification	(27,356)	27,356	(330,030)	(303,21
Change in net assets from nonoperating activities	(287,669)	898,473	610,804	771,66
Change in net assets	(213,553)	936,956	723,403	1,076,47
Net assets at beginning of year	8,502,576	11,291,723	19,794,299	18,717,82
Net assets at end of year	\$8,289,023	\$12,228,679	\$20,517,702	\$19,794,29

See accompanying notes to the consolidated financial statements.

# The Trustees of Columbia University in the City of New York Consolidated Statements of Cash Flows For the Years Ended June 30, 2025 and 2024 (in thousands of dollars)

	June 2025	June 2024
Cash flows from operating activities		
(Includes adjustments to reconcile change in net assets to net cashlow from operating activities):		
Change in net assets	\$723,403	\$1,076,479
Depreciation expense and loss on disposal of assets	325,867	337,969
Institutional real estate depreciation	38,962	34,525
Change in right of use leases and interest on finance lease obligations and	14.505	12.700
conditional asset retirement obligations	14,795	13,799
Realized and unrealized gains Partnership distributions from endowment	(1,548,745) 581,439	(1,418,931) 768,234
Contributions restricted for permanent investment,	301,737	700,234
plant, and split-interest agreements	(199,369)	(350,831)
Contributions other than cash	(139)	(126)
Present value adjustments and	()	()
actuarial liability for split-interest agreements	(23,965)	(25,841)
Accreted interest on bonds	262	315
Change in unamortized bond premium and issuance costs	(28,559)	(27,700)
Change in fair value of net assets held by CPMC Fund, Inc.	(942)	(586)
Change in fair value of interest in perpetual trusts held by others	(15,313)	(19,725)
Change in operating assets and liabilities:		
Accounts receivable, net	(258,450)	(68,960)
Pledges receivable, net	(31,420)	50,950
Other assets	(2,501)	(22,613)
Accounts payable and accrued expenses	29,555	169,248
Deferred revenue and other prepayments Accrued employee benefit liabilities	5,607 68,563	(8,021) 71,795
Conditional asset retirement obligations and other long-term liabilities	(136,502)	110,912
Net cash (used in) / provided by operating activities	(457,452)	690,892
Net cash (used in) / provided by operating activities	(437,432)	090,092
Cash flows from investing activities		
Proceeds from sales of investments	4,303,102	2,981,783
Purchases of investments	(4,046,410)	(3,025,804)
Collections from student notes	7,733	8,893
Student notes issued	(2,991)	(3,426)
Investment in cash and securities held in trust by others	(26)	25,319
Purchases of institutional real estate	(70,962)	(111,691)
Purchases of plant and equipment	(328,595)	(285,026)
Net cash used in investing activities	(138,149)	(409,952)
Cash flows from financing activities		
Proceeds from contributions for:		
Investment in endowment	161,024	263,571
Investment in plant	35,170	65,561
Investment in split-interest agreements	3,175	21,699
Investment income on split-interest agreements	4,223	4,063
Payments on split-interest agreements	(6,050)	(5,967)
Payments on finance lease obligations	(13,107)	(11,849)
Repayment of taxable commercial paper		(25,188)
Proceeds from tax exempt commercial paper issuance	105,000	
Repayment of bonds and notes payable	(65,250)	(101,710)
Proceeds from bond and note issuance	525,753	
Net change in federal student loan funds	(2,818)	(5,337)
Net cash provided by financing activities	747,120	204,843
Not abanco in each and each equivalents	151 510	195 792
Net change in cash and cash equivalents Cash and cash equivalents at beginning of year	151,519 1,007,124	485,783 521,341
Cash and cash equivalents at end of year	\$1,158,643	\$1,007,124
	\$1,130,043	\$1,007,124
Supplemental disclosures of cash flow information:	¢1 145 220	0074 557
Cash and cash equivalents as shown in the Statements of Financial Position	\$1,145,338	\$974,557
Cash included in Investments, at fair value (see Note 5)  Total cash and cash equivalents as shown on the Consolidated Statements of Cash Flows	13,305 \$1,158,643	32,567 <b>\$1,007,124</b>
		\$1,007,124
Change in accounts payable for land, buildings, and equipment	\$13,194	(\$10,667)
Equipment and space acquired through finance lease obligations	\$10,844	\$3,878
Right of use, lease assets acquired through new right of use lease obligations	\$33,958	\$15,518
Cash paid during the year for interest	\$102,341	\$91,249

See accompanying notes to the consolidated financial statements.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 1. Organization

The Trustees of Columbia University in the City of New York (the "University") is a private, nonsectarian, nonprofit institution of higher education, recognized as tax exempt under Section 501(c)(3) of the Internal Revenue Code, whose activities are concentrated at three locations in New York City and extend around the globe. The University provides instruction through seventeen undergraduate, graduate, and professional schools. It operates a variety of research institutes and a library system to support its teaching, learning, and research activities. The University performs research, training, and other services under grants and contracts with agencies of the federal government and other sponsoring organizations. The University enrolls 35,769 full-time and part-time students.

# **Columbia University Irving Medical Center**

Columbia University Irving Medical Center ("CUIMC"), a division of the University, located in the Washington Heights section of northern Manhattan, is one of the largest academic medical centers in the United States. It is composed of four schools: Vagelos College of Physicians and Surgeons, Mailman School of Public Health, College of Dental Medicine, and School of Nursing.

CUIMC has three primary areas of focus: patient care, scientific research, and education. Patient care activities include patient visits performed by Columbia faculty through its medical faculty practice plan, as well as clinical, educational and administration services provided to hospitals and other health care institutions through contractual agreements for services in the form of interinstitutional professional service agreements and medical service agreements. CUIMC faculty provide patient care in specialty and subspecialty areas at hospitals in the tristate area and in other parts of the country and the world. CUIMC offers a wide variety of degrees, certifications, and continuing education in health sciences.

CUIMC maintains several clinical and education affiliation agreements with other organizations. The most significant affiliation agreements are with New-York-Presbyterian (NYP), Lawrence Hospital, and Harlem Hospital. The majority of CUIMC's full-time faculty hold clinical appointments and have admitting privileges at NYP/CUIMC Campus. Certain faculty physicians also provide patient care and supervision of residents at NYP network hospitals and other affiliates.

### **Other Activities**

The University holds a number of limited liability companies, not-for-profit corporations and international organizations, which are established to facilitate various program and research objectives, and the results of which are included in the University's consolidated financial statements, including:

- Columbia Investment Management Company, LLC, a New York limited liability company
  formed by the University to manage the University's investment assets under the
  supervision of a Board appointed by the Trustees of the University and subject to the
  oversight of the Committee on Finance of the Trustees.
- Reid Hall Inc., located in Paris, France, which was donated to the University in 1964. Reid Hall, Inc., a corporation organized under New York membership corporation law as an educational and charitable organization, operates Reid Hall to promote, facilitate, and aid the educational, cultural, and social interests of students studying in France.
- Columbia University Healthcare, Inc., a not-for-profit practice entity in which the University is the sole corporate member.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

• ColumbiaDoctors of New Jersey, P.C., ColumbiaDoctors of Bergen County, P.C. and ColumbiaDoctors of Connecticut, P.C., which are professional corporations in which the University is the sole corporate member.

# 2. Summary of Significant Accounting Policies

The significant accounting policies of the University are as follows:

### **Basis of Consolidation**

The consolidated financial statements of the University include the accounts of all academic and administrative departments of the University.

All significant intercompany accounts have been eliminated in consolidation.

### **Basis of Presentation**

The University maintains its accounts in accordance with the principles of fund accounting. Under this method of accounting, resources for various purposes are classified into funds that are consistent with activities or objectives specified by donors. Separate accounts are maintained for each fund.

For reporting purposes, the University prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"), including the provisions of Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 958 Not-for-Profit Entities that requires resources be classified for reporting purposes based on the existence or absence of donor-imposed restrictions. Accordingly, the University classifies fund balances as without donor restrictions or with donor restrictions.

The consolidated financial statements of the University have, in all material respects, been prepared on an accrual basis.

### **Revenues and Expenses**

Revenues are reported as increases in net assets without donor restrictions unless the use of those assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments are reported as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor stipulation or by law.

# **Revenue Recognition**

Revenue related to exchange transactions is recognized under the provisions of the applicable ASC Topic, which is typically ASC Topic 606, Revenue from Contracts with Customers.

The University recognizes contributions in accordance with the revenue recognition provisions of ASC Topic 958-605, Not-for-Profit Entities. Revenue is considered a contribution if it is determined not to be an exchange transaction.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

Revenue recognition for the University's significant types of revenue is discussed below.

### Tuition, Fees, Room and Board, and Financial Aid

Student related income includes Tuition and fees revenue derived from degree programs as well as executive and continuing education programs and room and board revenue derived from the provision of such related services to students; these revenues are recorded in "Tuition and fees" and "Sales and services of auxiliary enterprises", respectively. Gross revenue is based on published rates and is recorded net of explicit price concessions such as financial aid grants which are applied to tuition and fees. Revenue is recognized in the period in which the University satisfies its performance obligations to its students. Given the timing of each year's academic sessions, nearly all performance obligations on behalf of the University are completed within the fiscal year.

The timing(s) of billings, cash collections and revenue recognition results in accounts receivable, deferred revenue and student deposits on the consolidated statements of financial position. Receivables are recognized only to the extent that is it probable that the University will collect substantially all of the consideration to which it is entitled in exchange for goods and services transferred to the student. Receipts received in advance of goods and services performed are recorded as deferred revenue or student deposits.

## Contributions and Pledges Receivable

Contributions for University operations and plant, including unconditional promises to give ("pledges"), are recognized as operating revenue in the period received. Contributions to endowment are recognized as nonoperating revenue in the period received. Amounts expected to be collected in future years are recorded at the present value of estimated future cash flows, net of an allowance for uncollectable pledges. The discounts on those pledges are computed using an interest rate for the year in which the promise was received and considers market and credit risk as applicable. Subsequent years' accretion of the discount is included in contribution revenue. Conditional promises to give are not recognized as revenue until such time as the conditions are met.

## **Grant and Contract Income**

The University receives sponsored program grant and contract income from governmental and private sources. The funding may represent a nonreciprocal transaction in which the resources provided are for the benefit of the University, the funding organization's mission, or the public at large or it may be a reciprocal transaction in exchange for an equivalent benefit in return.

Revenues from exchange transactions are recognized as performance obligations are satisfied which in most cases mirrors the timing of when related costs are incurred. Revenues from non-exchange transactions may be subject to conditions in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). The University recognizes revenue earned from conditional non-exchange transactions when the barrier is satisfied, typically as related costs are incurred. At June 30, 2025, the University has grants or contracts for which it has not yet met all obligations to recognize revenue, or the right to recognize revenue is dependent on future events. These open commitments total \$3.0 billion and it is expected that revenue will be recognized as the University fulfills its obligations over several years. In addition, the University has elected the simultaneous release option for conditional contributions that are also subject to purpose restrictions. Under this option, net assets without donor restrictions will include the donor-restricted contributions if the purpose restrictions are met in the same reporting year as the revenue is recognized.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

Indirect cost recoveries on federally sponsored programs, such as the recovery of facilities and administrative (F&A) costs, are at reimbursement rates negotiated with the University's cognizant agency, the Department of Health and Human Services. Amounts totaled \$341.0 million and \$348.9 million in fiscal years 2025 and 2024, respectively, and are included in Government Grants and Contracts.

### Patient Care Revenue

Patient care revenue relates to four distinct areas: medical faculty practice plans, affiliation agreements, medical and professional service agreements, and dental clinic.

The University recognizes "Patient care revenue" when the performance obligations under contracts are satisfied. Revenue related to the unsatisfied obligations will be deferred into the following fiscal year. The University determines transaction price based on gross charges for services provided, reduced by explicit price concessions based on agreements with third-party payers, and implicit price concessions which are reflected as an allowance for doubtful accounts. Allowance for doubtful accounts is determined based on its historical collection experience with these classes of patients using a portfolio approach, as well as current and future conditions that may further impact collectability.

- Medical faculty practice and Dental Clinic revenues are reported at the estimated net realizable amounts from patients, third-party payers, and others for services rendered. These revenues are \$1,120.8 million and \$1,091.9 million for the years ended June 30, 2025 and 2024, respectively, derived mainly from third-party payers, including commercial insurance and managed care companies (57 percent), Medicare (18 percent), Medicaid (14 percent), direct patient payment (10 percent), and other (1 percent). As of June 30, 2025 and 2024, patient accounts receivable, included within "Accounts receivable, net", amounts to \$112.2 million and \$115.9 million, respectively.
- The University's affiliation agreements with area hospitals generated \$589.0 million and \$538.0 million of revenue for the years ended June 30, 2025 and 2024, respectively. As of June 30, 2025 and 2024, "Accounts receivable, net" includes \$184.1 million and \$164.0 million, respectively, relating to these agreements.
- Medical service agreements generated \$61.7 million and \$48.2 million of revenue for the years ended June 30, 2025 and 2024, respectively, and other patient care activities generated \$125.3 million and \$105.7 million of revenue for the years ended June 30, 2025 and 2024, respectively.

Patient care revenue is supported by Patient care expenses, which include direct expenses associated with providing patient care services, as well as administrative functions within the University's faculty practice organization. Patient care expense does not include rent or utilities in clinical space, as those costs are aggregated with all University space costs within "Operation and maintenance of plant" in the consolidated statements of activities.

# Research and Development

The University engages in numerous research and development projects, which may be partially or fully sponsored by governmental and private funds. These costs are charged to operating expense as incurred. The University periodically funds and develops patents for certain technologies, then licenses the usage of these patents to companies for a specified period of time. The revenue, net of

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

payments due to third parties, is recorded in "Revenue from other educational and research activities" in the consolidated statements of activities. Costs incurred with developing and maintaining these patents are expensed as incurred.

# **Institutional Support**

Institutional support expense includes central administrative functions and expenses that support the management of the University. This category also includes any net operating surplus or deficit of the University's benefit pool, as recoveries from units across the University may be less than or greater than benefits paid in a given year.

# **Cash and Cash Equivalents**

Cash and cash equivalents are recorded at fair value; those that are not part of the University's investment portfolio include several depository accounts, checking accounts, institutional money market funds, and similar temporary investments with maturities of three months or less at the date of purchase. The University has elected to classify cash equivalents that are part of the University's investment portfolio as short-term investments within "Investments, at fair value" in the consolidated statements of financial position.

### **Investments**

The University's investments, consisting primarily of publicly traded fixed income and equity securities, alternative investments, and cash held for reinvestment, are stated at fair value as of June 30, 2025 and 2024. Alternative investments include investments in absolute return strategy funds, private equity funds, and real asset funds. The management of each respective fund provides the fair value of the investment. The University reflects its share of the partnerships or corporations in the consolidated financial statements.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The University believes that the net asset value of its alternative investments is a reasonable estimate of fair value as of June 30, 2025 and 2024. Because alternative investment funds are not marketable, the estimated value is subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market for the investment existed. Such differences could be material. The amount of gain or loss associated with these investments is reflected in the consolidated financial statements based on the University's proportionate share in the net assets of these investments.

The University's presentation in the consolidated statements of cash flows for limited liability partnerships, limited liability corporations, and other similarly structured investments is consistent with the accounting for equity method investments as it represents the underlying nature of these investments in which the University has a capital account.

The University records purchases and sales of securities on a trade-date basis. Realized gains and losses are determined on the basis of average cost of securities sold and are reflected in the consolidated statements of activities. Dividend income is recorded on the ex-dividend date, and interest income is recorded on an accrual basis.

## **Split-Interest Agreements**

The University's split-interest agreements with donors consist primarily of charitable gift annuities, pooled income funds, and irrevocable charitable remainder trusts for which the University serves as

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

custodian and trustee. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements.

Contribution revenues for split-interest agreements are recognized at the dates the agreements are established net of the present value of the estimated future payments to be made to the beneficiaries, if applicable, under these agreements. The discounts on those agreements are computed using an interest rate for the year in which the contribution was received and considers market and credit risk as applicable. Assets related to these agreements are recorded in "Investments, at fair value" and the liability for the present value of the estimated future payments to be made to the beneficiaries is recorded in "Other long-term liabilities" in the consolidated statements of financial position. Adjustments to the fair value of these agreements are recorded in the consolidated statements of activities under "Present value adjustment to split-interest agreements".

### **Institutional Real Estate**

Institutional real estate consists primarily of properties proximate to the University's campuses, the primary purpose of which is to house faculty, staff, and graduate students. The income earned on this investment is used primarily to finance operating expenditures. The properties are valued at cost and depreciated over useful lives ranging from twelve and one half to fifty years.

# Land, Buildings, and Equipment

Land, buildings, and equipment are stated at cost net of accumulated depreciation. Depreciation is calculated on a straight-line basis over useful lives ranging from ten to one hundred years for buildings and building improvements and two to twenty years for equipment, consistent with the method used for government cost reimbursement purposes. Capitalized software costs are amortized over seven years. Upon disposal of assets, the costs and accumulated depreciation are removed from the accounts, and the resulting gain or loss is included in the consolidated statements of activities.

### **Collections**

The University's collections include works of art, literary works, historical treasures and artifacts maintained in the University's libraries and museums. These collections are protected and preserved for public exhibition, education, research, and the furtherance of public service. Proceeds realized from deaccessioning collection items are to be used for the acquisition of new items for the University's collection and/or enhancing the life, usefulness or quality of the existing collection through long-term direct care and preservation, which includes conservation care, cataloging and documenting and proper access and use of the collection. Accordingly, such collections are not capitalized and contributed items are not recognized as revenue for financial statement purposes.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# **Interest in External Trusts Held by Others**

The University is the beneficiary of certain external trusts administered by others, including irrevocable split-interest agreements and perpetual trusts. These trusts are recognized as contributions with donor restrictions when the University receives sufficient reliable information and documentation that establishes the trust's existence, the University's beneficial interest, and the value of that interest. The net value is recorded in "Investments, at fair value" in the consolidated statements of financial position. Adjustments to the fair value of the University's interest are reported as "Present value adjustment to split-interest agreements" and "Change in funds held by others in perpetuity", respectively, in nonoperating activity in the consolidated statements of activities.

### Leases

The University records lease arrangements for space and equipment in accordance with ASU 2016-02, Leases (Topic 842). Arrangements in which substantially all of the risks of ownership have been transferred to the University are accounted for as finance leases and extend up to seven years for equipment and up to 50 years for space.

Arrangements which do not qualify for finance lease treatment but still provide the University the right to use the underlying asset are deemed to be right of use leases. These leases are recorded on the statements of financial position as "Right of use, lease assets" offset by "Right of use, lease obligations". The University has elected the short-term lease exemption policy which permits an entity to not capitalize short-term leases in its statements of financial position. The University uses an incremental borrowing rate for discounting leases, as applicable, and has elected to separate lease and non-lease components in the calculation. Right of use leases typically extend up to five years for equipment and up to 20 years for space.

## **Conditional Asset Retirement Obligations**

Conditional asset retirement obligations are recognized for remediation or disposal of asbestos, underground storage tanks, soil, and radioactive sources and equipment as required by law. The fair value of the liability is recognized in the period in which it occurred, provided that it can be reasonably estimated.

## **Other Long-Term Liabilities**

Other long-term liabilities are obligations that extend beyond one year, or operating cycle, whichever is longer. The obligations for medical malpractice liabilities, self-insurance reserves, the fixed payer interest rate swap agreement, split-interest agreement liabilities, and other commitments are categorized in other long-term liabilities.

### **Use of Estimates**

Management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates include valuation of investments without readily determinable prices in active markets, useful lives of depreciable assets, actuarially determined costs associated with split-interest agreements, pension, postemployment and postretirement benefits, explicit and implicit price concessions for patient and other receivables, insurance obligations, and conditional asset retirement obligations.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# **2024 Presentation**

Within the consolidated statements of activities, prior year presentation of net asset categorization has been condensed for comparative purposes. Accordingly, such information should be read in conjunction with the University's audited consolidated financial statements for the year ended June 30, 2024. Further, certain prior year information has been reclassified to conform to current year presentation.

### 3. Net Assets

The University classifies its net assets as without donor restrictions or with donor restrictions. Periodically, donor redesignations may result in reclassifications of net assets. Descriptions of the two net asset categories and the types of transactions affecting each category follow.

Without Donor Restrictions—Net assets that are not subject to explicit donor-imposed restrictions. This category includes funds designated by the Board of Trustees to function as endowment and other undesignated funds such as tuition and other current funds, gifts without restrictions (including gifts whose donor-imposed restrictions were met during the fiscal year), net investment in plant, and student loan funds.

With Donor Restrictions—Net assets that are subject to explicit donor-imposed stipulations. This includes net assets with donor restrictions that will be satisfied by actions of the University, the passage of time, or both. These net assets include gifts for which the donor-imposed restriction(s) have not been met in the year of receipt (including gifts for capital projects not yet placed in service), pledges, split-interest agreements, and net assets from donor-restricted endowments not yet appropriated for spending. Once the restrictions are satisfied, or deemed satisfied, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Also included in this category are net assets with donor restrictions that require these to be maintained permanently by the University and invested to provide a perpetual source of income. Net assets with donor restrictions that are permanent include (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) realized and unrealized gains and losses to the permanent endowment when stipulated by the donor gift instrument.

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The composition of the University's net assets as of June 30 are as follows:

	 2025	 2024
With Donor Restrictions	_	 
Endowment funds	\$ 10,874,411	\$ 10,003,613
Unexpended capital and other (a)	608,413	584,838
Pledges receivable	565,308	533,888
Annuity and life income funds	 180,547	169,384
Total, Net Assets With Donor Restrictions	 12,228,679	 11,291,723
Without Donor Restrictions		
Board designated endowment	5,043,079	4,778,879
Undesignated	 3,245,944	 3,723,697
Total, Net Assets Without Donor Restrictions	8,289,023	8,502,576
Total Net Assets	\$ 20,517,702	\$ 19,794,299

<sup>(</sup>a) Includes capital gifts not yet released from restriction, unspent gift and endowment income balances, and student loan funds.

# 4. Operating Measurement

The University divides its consolidated statements of activities into operating and nonoperating activities. The operating activities of the University include all income and expenses related to carrying out its mission focused on education, research, and patient care. Operating revenues include investment income and endowment appreciation utilized to fund current operations, the largest portion of which is the distribution of funds budgeted in accordance with the endowment spending rule.

Nonoperating activities include current year realized and unrealized gains and losses on investments, including realized gain distributions from fund investments, less amounts withdrawn from endowment appreciation to fund operations. Nonoperating activities also include new gifts to donor-restricted endowments that the University must hold in perpetuity, changes in net assets held by Columbia-Presbyterian Medical Center (CPMC) Fund, Inc., changes in funds held by others in perpetuity, present value adjustments to split-interest agreements, net periodic benefit cost other than service cost, changes in pension and postretirement obligations, gains or losses on the defeasance of debt, reclassifications, certain uninsured losses or settlements, and/or other items unique or one time in nature.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 5. Long-Term Investments and Fair Value

The University values its investments at fair value for financial assets and liabilities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value utilize relevant observable inputs and minimize the use of unobservable inputs.

The University follows a fair value hierarchy based on three levels of inputs, described below:

Fair value for Level 1 is based on quoted prices in active markets that the University has the ability to access for identical assets and liabilities. Market price data is generally obtained from exchange or dealer markets. The University does not adjust the quoted price for such assets and liabilities.

Fair value for Level 2 is based on quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other significant market-based inputs that are observable, either directly or indirectly.

Fair value for Level 3 is based on valuation techniques that use significant unobservable inputs, as they trade infrequently or not at all. The inputs into the determination of fair value are based upon the best information in the circumstance and may require significant management judgment.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In determining the categorization of the University's investments within the fair value hierarchy, the University has considered market information including observable net asset values and the length of time until the investment will become redeemable. Investments for which fair value is measured using net asset values ("NAV") as a practical expedient are excluded from the hierarchy and have been reported separately within the table below. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of that instrument and does not necessarily correspond to the University's perceived risk of that instrument.

The University holds certain investments for which fair value is determined generally by using the unadjusted NAV per share as provided by the fund manager as a practical expedient. Investments categorized as NAV include the University's ownership in funds that invest in alternative assets (i.e. absolute return strategy funds, private equity funds, and real asset funds) and funds that invest in equity and fixed income strategies for which observable net asset values are not available. The value of the University's investments in these funds represents the University's ownership interest in the net asset value of the respective fund. Items classified as NAV do not have a quoted price in an active market place. As a practical expedient, the University estimates the fair value of an investment at the measurement date using the NAV reported by the fund manager without further adjustment, provided the NAV has been calculated in accordance with or in a manner consistent with GAAP, and provided further that the University does not expect to sell the investment at a value other than NAV. The University has various processes and controls in place to ensure investment fair value is reasonable and performs various due diligence procedures over its

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

investments including an assessment of applicable accounting policies, a review of the valuation procedures employed, and consideration of redemption features and price transparency.

The following tables present assets measured at fair value and NAV at June 30, 2025 and June 30, 2024.

				2025				
	Level 1	Level 2		Level 3		NAV		Total
Investments:								
Short-term investments	\$ 185,909	\$ 474,100					\$	660,009
Global equities	1,328,269	9,457	\$	101	\$	4,443,868		5,781,695
Fixed income	207,780	29,364						237,144
Absolute return strategies						3,889,081		3,889,081
Private equity	55,518			93,367		3,910,304		4,059,189
Real assets	454			9,372		1,403,855		1,413,681
Interest in external charitable trusts				357,607				357,607
Subtotal, Investments	1,777,930	512,921		460,447		13,647,108		16,398,406
Net receivables (payables)	_	 						55,621
Investments, at fair value							\$	16,454,027
				2024				
	Level 1	Level 2		Level 3		NAV		Total
Investments:								
Short-term investments	\$ 302,388	\$ 603,243					\$	905,631
Global equities	759,694	9,870	\$	59	\$	3,723,722		4,493,345
Fixed income	303,913	202,669						506,582
Absolute return strategies						3,878,073		3,878,073
Private equity	5,461			89,659		3,632,807		3,727,927
Real assets	1,764			8,070		1,676,211		1,686,045
Interest in external charitable trusts				335,236				335,236
Subtotal, Investments	1,373,220	815,782		433,024		12,910,813		15,532,839
Net receivables (payables)								189,533
Investments, at fair value							\$	15,722,372

## **Short-Term Investments**

Short-term investments include government securities and money market instruments and are valued at amortized cost, which approximates fair value.

# **Global Equities and Fixed Income**

Global equities and fixed income consist of investments in publicly traded U.S. and foreign common and preferred equities, funds that invest in equity and fixed income based strategies, and cash held in separate accounts committed to these strategies. The fair value of these investments is based on quoted market prices. Investments that are listed on an exchange are valued, in general, at the last reported sale price (or, if there is no sales price, at the last reported bid price, or, in the absence of reported bid prices, at the mean between the last reported bid and asked prices thereof). Fund investments in equity and fixed income based strategies are valued in accordance with NAV provided by the investment managers of the underlying funds.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

### **Alternative Investments**

Alternative investments include absolute return strategies, private equity, and real assets. Holdings in these strategies may be in funds or in separate accounts with direct investments in listed equities and fixed income, as well as cash committed to fund these investments. Private equity funds include large market, leveraged buyout, and venture capital based strategies. The University values these investments in accordance with valuations provided by the investment managers of the underlying funds. Investments in securities that are publicly traded, whether held by a fund or in a separate account, are generally valued based on observable market prices unless a restriction exists. In addition, investments in a private equity fund may be publicly traded and valued based on observable market prices.

As a general rule, alternative investments are valued based upon the best information available for a given circumstance and may incorporate assumptions that are the best estimate after consideration of a variety of internal and external factors. The fair value of investments categorized as Level 1 are based on quoted prices on a public market. If no public market exists for the investments, the fair value is determined by taking into consideration, among other things, the last reported bid price obtained from pricing sources or broker quotes, the cost of the investment, prices of recent significant placements of similar investments of the same issuer, and subsequent developments concerning the companies to which the investments relate. The University's management may consider other factors in assessing the fair value of these investments.

The fair value of the alternative investment funds in the table above represents the amount the University would expect to receive at June 30, 2025 and 2024, if it had liquidated its investments on these dates. The University has performed due diligence around these investments and believes that the NAV of its alternative investments is a reasonable estimate of fair value as of June 30, 2025 and 2024. Alternative investments may allocate a high percentage of their assets in specific sectors of the market in order to achieve a potentially greater investment return. As a result, the investments may be susceptible to economic, political, and regulatory developments in a particular sector of the market, positive or negative, and may experience increased volatility in net asset values.

From time to time, the University may hold direct real estate investments. These investments are categorized as Level 3 within the fair value hierarchy. Valuation for material directly held real estate investments is determined from periodic valuations prepared by independent appraisers or broker opinions.

## **Interest in External Trusts Held by Others**

The fair value of interest in perpetual trusts held by others is based on the University's share of the income generated by the trust, ascribed to the fair value of the assets reported by the trust.

The fair value of irrevocable split-interest agreements held by others is based on the University's share of the trust assets, net of the present value of the estimated future payments to be made to the beneficiaries, if applicable, under these agreements. The discounts on those agreements are computed using an interest rate for the year in which the contribution was received and considers market and credit risk as applicable.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

### **Derivatives**

Investment fund managers may invest in derivatives, and the value of these positions is reflected in the NAV of the respective funds. Separately, the University employs derivatives primarily to hedge its risks and to rebalance its market exposures. Derivatives used may include futures, swaps, options, and forward contracts and are reflected at fair value following the definition of Level 1 and Level 2 assets as described above. The derivatives are reflected as a receivable or payable, as appropriate, on the consolidated statements of financial position. Unrealized gain or loss from derivative investments is a component of the "Current year realized and unrealized capital gains (losses)" in the consolidated statements of activities. Certain derivative positions held within the endowment portfolio are subject to master netting agreements included within an International Swap and Derivatives Association, Inc. ("ISDA") master agreement with each of the counterparties.

The following positions are reflected on a net basis within "Investments, at fair value" on the consolidated statements of financial position and are summarized below.

	Notional	Exposure Gross		Net		Collateral			
<b>Derivative Instruments</b>	Long	Short	1	Asset	Liability	Fai	r Value		Posted
June 30, 2025									
Equity Currency	\$ 82,550		\$	1,381		\$	1,381	\$	13,286
June 30, 2024									
Equity Currency	\$ 538,622		\$	1,262		\$	1,262	\$	32,566

The University also holds a fixed payer interest rate swap as described in Note 15, reported in "Other long-term liabilities" on the consolidated statements of financial position. The estimated fair value of the agreement is reported as a liability of \$24.6 million and \$23.8 million at June 30, 2025 and 2024, respectively, and is considered a Level 2 measurement.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the University believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The following tables roll forward the amounts reported in the consolidated statements of financial position for financial instruments classified by the University within Level 3 of the fair value hierarchy defined above at June 30, 2025 and 2024.

	June 30, 2024	Transfers In/Out	Pu	rchases	Sales/ Disburse- ments	Realize Unrealize gain/loss	zed	J	June 30, 2025
Global equities	\$ 59					\$	42	\$	101
Private equity	89,659			14,847	(6,732)	(4,4	407)		93,367
Real assets	8,070			550			752		9,372
Interest in external charitable trusts	335,236			15,314	(4,877)	11,	934		357,607
Total level 3 investments	\$ 433,024		\$	30,711	\$ (11,609)	\$ 8,	321	\$	460,447

	June 30, Transfers 2023 In/Out I		Purchases	Dis	Sales/ Disburse- ments		Realized/ nrealized n/loss, net	J	June 30, 2024	
Global equities	\$ 633						\$	(574)	\$	59
Private equity	88,074	(63	0)	14,623		(4,461)		(7,947)		89,659
Real assets	8,086			46				(62)		8,070
Interest in external charitable trusts	 282,008			15,117		(7,679)		45,790		335,236
Total level 3 investments	\$ 378,801	\$ (63	0)	\$ 29,786	\$	(12,140)	\$	37,207	\$	433,024

All net realized and unrealized gains (losses) in the tables above are reflected in the consolidated statements of activities. Net unrealized gains (losses) relate to those financial instruments held by the University at June 30, 2025 and 2024. The University's policy is to recognize transfers in and transfers out as of the end of the period. Transfers between Level 3 and Level 1, Level 3 and Level 2 as well as between Level 3 and NAV are reported at gross, due to the criteria described above. There were no significant transfers between Level 1 and Level 2 for the years ended June 30, 2025 and 2024. There were no transfers between NAV and Level 2 for the years ended June 30, 2025 and 2024.

Certain investments in global equities and absolute return strategies may be subject to restrictions that (i) limit the University's ability to withdraw capital after such investment and (ii) limit the amount that may be withdrawn as of a given redemption date. The redemption terms of the University's investments in global equity and absolute return strategy funds vary from daily to triennial, with a portion of these investments designated as "illiquid" in "sidepockets" and that portion may not be available for withdrawal until liquidated by the investing fund and redemption notice periods range from 0 days to 180 days. Generally, as noted above, the University has no discretion as to withdrawal of its investment in private equity and real asset funds; distributions are made when sales of assets are made within the funds. In general, the remaining life of these private equity and real asset funds is up to 12 years.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The University is obligated under certain investment fund agreements to advance additional funding up to specified levels over a period of several years. These commitments have fixed expiration dates and other termination clauses. At June 30, 2025, the University had unfunded commitments of approximately \$2.4 billion as follows:

Asset class (\$ in millions)	Remaining life of fund	funded mitments	Timing to draw commitments
Global equities	N/A		1 to 8 years
Absolute return strategies	N/A	\$ 38	1 to 5 years
Private equity	1 to 12 years	1,856	1 to 12 years
Real assets	1 to 12 years	519	1 to 12 years
Total		\$ 2,413	

The University's estimate of the lives of the funds could vary significantly depending on the investment decisions of the external fund managers, changes in the University's portfolio, and other circumstances. Furthermore, the University's obligation to fund the commitments noted above may be waived by the fund manager for a variety of reasons including market conditions and/or changes in investment strategy.

The University has various sources of internal liquidity at its disposal, including cash, short-term investments, marketable debt and equity securities, and lines of credit, which are available to fund the committed drawdowns.

## **Investment Return**

Investment income and gains utilized on the consolidated statements of activities contains endowment appreciation utilized to fund the spending rule, institutional real estate revenue net of operating expenses and depreciation, and other investment income. "Endowment appreciation utilized" was \$721.4 million and \$694.3 million during 2025 and 2024, respectively. "Current year realized and unrealized capital gains (losses)" reported in nonoperating activities reflect investment returns net of external and direct internal investment costs. "Endowment appreciation utilized" reflects the associated funding of the spending rule.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

### 6. Endowment Funds

The University's endowment consists of approximately 6,700 separate funds established over many years for a wide variety of purposes, which include support of specific schools or departments of the University, professorships, research, faculty support, scholarships and fellowships, library, building construction, and other purposes. The endowment includes donor-restricted endowments and funds designated by the Board of Trustees to function as endowments. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The University employs a market value unit method of accounting for pooled general investments. Each participating fund enters and withdraws from the pooled investment account based on monthly unit market values. Changes in the market value of investments are distributed proportionately to each fund that participates in the investment pool. Net investment income distributed during the year is allocated on a per unit basis to each participating fund.

### **Relevant Law**

Under New York Prudent Management of Institutional Funds Act ("NYPMIFA"), the University may appropriate so much of a donor-restricted endowment fund as it deems prudent, considering the specific factors set forth in NYPMIFA and subject to the intent of the donor as expressed in the gift instrument. Unless stated otherwise in the gift instrument, the earnings in an endowment fund are considered to have donor restrictions until appropriated.

The University continues to classify as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. Accumulated appreciation on donor-restricted endowment funds is also included as net assets with donor restrictions until those amounts are appropriated for expenditure by the University in a manner consistent with the standard of prudence prescribed by NYPMIFA.

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The composition and changes in the University's endowment net assets as of June 30, 2025 and 2024, are as follows:

,	2025										
Changes in University endowment net assets		thout Donor Restrictions		With Donor Restrictions	Total						
Opening balance - June 30, 2024	\$	4,778,879	\$	10,003,613	\$	14,782,492					
Changes:											
Investment return		514,852		1,191,577		1,706,429					
New gifts		1,424		165,652		167,076					
Appropriation for expenditure		(280,282)		(544,924)		(825,206)					
Transfers		50,087		36,612		86,699					
Other / Reclassifications		(21,881)		21,881							
Closing balance - June 30, 2025	\$	5,043,079	\$	10,874,411	\$	15,917,490					
University endowment composition											
Donor-restricted endowment funds:											
Restricted in perpetuity			\$	4,711,527	\$	4,711,527					
Appreciation				5,379,269		5,379,269					
Board designated endowment:											
Departmental funds	\$	2,251,801		535,951		2,787,752					
University funds		1,808,285				1,808,285					
Institutional real estate, net		982,993				982,993					
CPMC Fund, Inc.				13,308		13,308					
Interests in perpetual trusts held by others				234,356		234,356					
University's endowment value	\$	5,043,079	\$	10,874,411	\$	15,917,490					

Note: The tables above do not include split-interest agreements, net of \$186,450 and pledges receivable, net of \$250,308.

Reconciliation to Investments, at fair value		
Investments, at fair value		\$ 16,454,027
Add:		
CPMC Fund, Inc.	13,308	
Institutional real estate, net	982,993	
Other receivables and payables	(4,083)	992,218
Subtract:		
Other long-term investments	(1,216,769)	
Split-interest agreements	(248,789)	
Funds held on behalf of others	(63,197)	(1,528,755)
University's endowment value		\$ 15,917,490

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

			2024		
					Total
-				•	13,642,667
\$	4,303,039	Þ	9,139,028	Ф	13,042,007
	452.007		1 000 607		1 401 524
	· · · · · · · · · · · · · · · · · · ·				1,481,534
	361		290,280		290,641
	(257,460)		(495,507)		(752,967)
	86,734		33,883		120,617
	(6,692)		6,692		
\$	4,778,879	\$	10,003,613	\$	14,782,492
		\$	4,532,273	\$	4,532,273
			4,732,900		4,732,900
\$	2,119,041		507,032		2,626,073
	1,706,212				1,706,212
	953,626				953,626
			12,366		12,366
			219,042		219,042
\$	4,778,879	\$	10,003,613	\$	14,782,492
	\$ \$	\$ 2,119,041 1,706,212 953,626	Restrictions \$ 4,503,039 \$  452,897 361 (257,460) 86,734 (6,692) \$ 4,778,879 \$  \$  \$ 2,119,041 1,706,212 953,626	Without Donor Restrictions         With Donor Restrictions           \$ 4,503,039         \$ 9,139,628           452,897         1,028,637           361         290,280           (257,460)         (495,507)           86,734         33,883           (6,692)         6,692           \$ 4,778,879         \$ 10,003,613           \$ 4,532,273         4,732,900           \$ 2,119,041         507,032           1,706,212         953,626           12,366         219,042	Without Donor Restrictions         With Donor Restrictions           \$ 4,503,039         \$ 9,139,628         \$           452,897         1,028,637         361         290,280           (257,460)         (495,507)         86,734         33,883           (6,692)         6,692         \$           \$ 4,778,879         \$ 10,003,613         \$           \$ 2,119,041         507,032           1,706,212         953,626         12,366           219,042         219,042

Note: The tables above do not include split-interest agreements, net of \$175,535 and pledges receivable, net of \$233,466.

## Reconciliation to Investments, at fair value

Investments, at fair value		\$ 15,722,372
Add:		
CPMC Fund, Inc.	12,366	
Institutional real estate, net	953,626	
Other receivables and payables	37,184	1,003,176
Subtract:		
Other long-term investments	(1,644,042)	
Split-interest agreements	(239,530)	
Funds held on behalf of others	(59,484)	(1,943,056)
University's endowment value		\$ 14,782,492

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# **Return Objectives and Risk Parameters**

Under the University's investment policies, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce performance which exceeds that of relevant indices for each asset class while assuming a moderate level of investment risk.

# **Strategies Employed for Achieving Objectives**

The University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University targets a diversified asset allocation to achieve its long-term return objectives within prudent risk constraints.

### **Endowment Spending Rule**

The endowment spending rule utilized by the University is designed to be directly responsive to both investment returns and the current level of price inflation. Its long-term objectives are:

- To protect the corpus of the endowment by spending no more than the real investment return;
- To cushion spending against market volatility; and
- To provide specific spending instructions and multiyear spending projections based on explicit future investment return assumptions.

The current endowment spending rule is based on two factors: first, the market value multiplied by a target spending rate of 4.5 percent, which provides a response to investment market conditions; and second, the prior year's spending plus inflation, which ties spending increases to operating needs and cushions spending against market volatility. This allows the University to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return.

As a general policy, each fiscal year's distribution is calculated by adding together the following:

- a. The market value of the endowment at a point twelve months prior to the beginning of the given fiscal year, multiplied by the target spending rate, multiplied by a 40 percent weighting; and
- b. Endowment spending in the year immediately preceding the given fiscal year, grown or reduced by an inflation factor, which is defined as the Higher Education Price Index ("HEPI"), multiplied by a 60 percent weighting.

The Trustees conduct a special review in any year in which either projected endowment distributions are 0.5 percent higher or lower than the target spending rate, or if the increase in endowment distributions over the previous year is more than 3 percentage points higher or lower than HEPI. Additionally, from time to time, management may recommend and the Trustees may approve a temporary override of the spending rule to ensure the University's ability to sustain the permanent nature of the endowment.

In addition to the base spending rate described above, an additional payout component was approved as a temporary measure by the Trustees in 2008, applied as a percentage of the prior year beginning market value for certain endowments in categories key to the University's current development efforts, primarily endowments for purposes core to the University's educational and research mission, including financial aid and faculty support. For the years ended June 30, 2025 and

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

2024 the additional payout rate was 0.55 percent and 0.55 percent, respectively. The additional payout component is reviewed by the Trustees regularly and has currently been extended through the end of fiscal year 2026. A limited term payout of 0.50 percent was also approved by the Trustees for fiscal year 2026 as part of the University's financial stabilization efforts, and will be distributed to endowments in the academic schools and certain central endowments in a manner similar to the additional payout.

### **Underwater Endowment Funds**

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the original gift value, which represents the total of the initial and subsequent donor contribution amounts. When this occurs, the deficit is classified as a reduction of donor-restricted net assets. As of June 30, 2025, no such deficits existed. As of June 30, 2024, deficits totaling \$0.5 million existed in funds which combined had an original gift value of \$25.5 million and a current market value of \$25.0 million. The deficits resulted from market fluctuations that occurred after the investment of recent contributions and authorized appropriation from an endowment that was deemed prudent.

### 7. Accounts Receivable

Accounts receivable, net, consists of the following as of June 30:

	2025	2024
Patient receivables, net of contractual allowances	\$ 159,739	\$ 162,613
Government agencies	347,514	147,143
New York-Presbyterian Hospital	204,036	190,243
Patent and licensing	8,953	7,992
Student receivables	119,584	103,120
Student loan receivable	35,447	40,173
Other receivables	260,008	227,814
	1,135,281	879,098
Less: Allowance for doubtful accounts	(76,369)	(73,894)
Accounts receivable, net	\$ 1,058,912	\$ 805,204

Patient receivables for medical services are net of an allowance for contractual reserves in the amount of \$340.2 million and \$321.1 million at June 30, 2025 and 2024, respectively.

The University participates in various federal loan programs, in addition to administering institutional loan programs.

Loans receivable from students are recorded in "Accounts receivable, net" and as of June 30 are as follows:

	 2025	2024
Government revolving loans	\$ 16,817	\$ 19,513
Institutional loans	 18,630	 20,660
Gross student loans	35,447	40,173
Less: Allowance for doubtful collections	 (2,158)	(2,142)
Student loans receivable, net	\$ 33,289	\$ 38,031

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

Government revolving loan programs include the Federal Perkins Loan Program and certain other programs. The total loans outstanding totaled \$5.7 million and \$7.9 million under the Federal Perkins Loan Program and \$11.1 million and \$11.6 million under the other programs as of June 30, 2025, and 2024, respectively. The Federal Perkins Loan Program has expired and no new disbursements were permitted after June 30, 2018, but there are outstanding balances from loans awarded in previous years.

Management regularly assesses the adequacy of the allowance for doubtful collections by performing ongoing evaluation of the student loan and student accounts receivable portfolios. Loans receivable under federally guaranteed student loan programs are subject to significant restrictions.

In addition to the loans identified above, the University processes and authorizes loans to students through the William D. Ford Federal Direct Loan Program. The amounts due under this loan program are not recorded in the University's consolidated financial statements since the University does not guarantee any federal loan funds related to this program. Loans issued under this program were \$301.5 million and \$309.2 million for the years ended June 30, 2025 and 2024, respectively.

### 8. Financial Aid

Financial aid grants applied to tuition revenue on the Statement of Activities represent student support amounts for both undergraduate and graduate students. Financial aid grants provided to undergraduate students are for all or part of a student's tuition and fees, and in certain other instances, items such as room and board. Financial aid grants provided to graduate students are for all or part of a student's tuition and fees. In addition, operating expenses include funds paid to students as support in the form of non-tuition aid, fellowships, compensation, employment-related tuition waivers, prizes and awards, and other payments.

Graduate financial aid grants Financial aid grants reported in net tuition  Student support payments reported in operating expenses  249,667  243		2025	2024
Student support payments reported in operating expenses 249,667 243	Graduate financial aid grants	348,502	\$ 261,406 333,627
Total aid provided to students \( \square \ 872,295 \) \( \square 838	Student support payments reported in operating expenses	249,667	243,370
	Total and provided to students	\$ 872,295	\$ 838,403

Students also receive grants and payments from federal and state governmental agencies and other external sources to assist with educational costs. These amounts are not reported in the University's Statement of Activities as the University serves a pass-through function. Associated receipts and disbursements are \$137.2 million and \$130.9 million in years ended June 30, 2025 and 2024, respectively.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 9. Pledges Receivable

Unconditional promises to give appear as pledges receivable and revenue with donor restrictions. Pledges are recorded net of an allowance for doubtful contributions and a discount to reflect the net present value based on projected cash flows. Periodically unconditional promises to give are reviewed for collectability. As a result, the allowance for doubtful contributions may be adjusted and some receivables may be adjusted or cancelled. Such changes will be reflected in "Pledges Receivable, net" in the consolidated statements of financial position.

Unconditional promises, and their expected collection dates, were as follows at June 30:

	2025	 2024
Less than one year	\$ 241,527	\$ 175,777
One to five years	313,601	336,290
More than five years	 185,886	 157,846
Total unconditional promises	 741,014	669,913
Less: Allowances and NPV discount	 (175,706)	(136,025)
Net pledges receivable	\$ 565,308	\$ 533,888

New pledges recorded in the years ended June 30, 2025 and 2024, were discounted at an average annual rate of 4.13 percent and 4.69 percent, respectively, using a rate that considers market and credit risk. Credit risk is also considered in the allowance for doubtful contributions.

Pledges receivable were intended for the following purposes as of June 30:

	 2025	2024
Endowment for educational and general purposes	\$ 250,308	\$ 233,466
New construction and modernization of plant	90,613	88,073
Support of University operations	224,387	212,349
Net pledges receivable	\$ 565,308	\$ 533,888

The University also has other conditional pledges and promises to give of \$652.3 million as of June 30, 2025, which are not currently reflected in the consolidated financial statements. These represent either gifts with donor-imposed conditions or other promises that have not yet met the requirements for recognition.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 10. Land, Buildings, and Equipment

Investments in land, buildings, and equipment, net, consisted of the following at June 30:

		2025					2024							
		Total Land, Buildings, and Equipment		ccumulated epreciation	Net Land, Buildings, and Equipment		Buildings, and		Bu	otal Land, ildings, and quipment		ccumulated epreciation	Bui	Net Land, ildings, and quipment
Land	\$	536,865			\$	536,865	\$	536,857			\$	536,857		
Building and building														
improvements		8,331,382		(4,572,083)		3,759,299		8,151,048		(4,304,239)		3,846,809		
Construction in progress		355,844				355,844		275,635				275,635		
Equipment		772,228		(547,854)		224,374		737,981		(521,418)		216,563		
Total	\$	9,996,319	\$	(5,119,937)	\$	4,876,382	\$	9,701,521	\$	(4,825,657)	\$	4,875,864		

Building and building improvements include physical assets owned by the University as well as leasehold improvements, financed space leases, and construction in progress. The net book value of financed space leases at June 30, 2025 and 2024, was \$65.7 million and \$68.7 million, respectively.

Equipment includes physical assets owned by the University as well as software costs and moveable equipment acquired through finance leases.

The University uses componentized depreciation to calculate depreciation expense for buildings and building improvements for research facilities included in operations. The costs of research facilities are separated into the building shell, building service systems, and fixed equipment, and each component is separately depreciated.

### 11. Accrued Employee Benefit Liabilities

Accrued employee benefit liabilities arise from employment at the University. These include liabilities for pension, postretirement benefits, postemployment benefits, unused vacation, and deferred compensation.

Postemployment benefits relating to workers' compensation, short-term disability, and continuation of medical benefits for those on long-term disability are provided to former or inactive employees after employment but before retirement. The University records the costs of such benefits on an accrual basis if the employee has provided the services from which those benefits are derived. As of June 30, 2025 and 2024, the actuarially computed liabilities on the University's consolidated statements of financial position are \$57.9 million and \$58.3 million, respectively and included in "Accrued employee benefit liabilities" in the consolidated statements of financial position.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

### 12. Pension and Other Postretirement Benefit Costs

### **Pension Plan Benefits**

The University has two non-contributory pension plans (the "pension plans") for supporting staff employees. Both pension plans include defined benefits for past and future service, and are subject to collective bargaining agreements.

In addition, the University provides retirement benefits for full-time faculty, officers, certain other employees, and supporting staff under various defined contribution plans. University contributions for the plans reported in operating expenses were \$229.8 million and \$212.7 million for the years ended June 30, 2025 and 2024, respectively.

## **Postretirement Health Care and Life Insurance Benefits**

The University provides postretirement health care and life insurance benefits for certain employees. The University accrues the estimated cost of these benefits over the years that eligible employees render service.

## **Obligations and Funded Status**

The University recognizes the difference between benefit obligations and any plan assets of the University's defined benefit and other postretirement benefit plans on the consolidated statements of financial position. In addition, unamortized amounts (e.g., net actuarial gains or losses and prior service cost or credits) are recognized as changes to net assets without donor restrictions and those amounts are adjusted as they are subsequently recognized as components of net periodic pension cost.

Cumulative amounts recognized in net assets without donor restrictions are as follows:

	 Pension P	lan Bo	enefits	 Other Post Ben	tretir efits	ement
	2025		2024	2025	2024	
Net actuarial (gain) / loss	\$ 17,248	\$	19,556	\$ (102,548)	\$	(85,792)
Prior service cost				54,397		18,561
Total amount recognized	\$ 17,248	\$	19,556	\$ (48,151)	\$	(67,231)

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The components of accrued benefit costs for pension benefits and other postretirement benefits are as follows:

	Pension Plan Benefits					Other Post Ben	retin efits				
		2025 2024		2024	2025			2024			
Change in benefit obligation:											
Benefit obligation, beginning of year	\$	219,001	\$	211,969	\$	124,659	\$	106,955			
Service cost		7,187		7,109		5,659		5,090			
Interest cost		12,711		11,859		7,543		6,581			
Plan participants' contributions						1,318		1,337			
Actuarial gain		(121)		(2,276)		(11,753)		(13,440)			
Federal subsidy						90		123			
Plan amendments						44,445		23,680			
Net disbursements and transfers		(9,908)		(9,660)		(6,106)		(5,667)			
Benefit obligation, end of year		228,870		219,001		165,855		124,659			
Change in plan assets:											
Fair value of assets, beginning of year		209,303		204,900		241,353		227,538			
Actual return on plan assets		14,995		8,017		25,139		18,145			
Employer contributions		6,877		6,045							
Plan participants' contributions						1,318		1,337			
Net disbursements and transfers		(9,908)		(9,659)		(6,106)		(5,667)			
Fair value of assets, end of year		221,267		209,303		261,704	_	241,353			
Net amount recognized	\$	(7,603)	\$	(9,698)	\$	95,849	\$	116,694			
Weighted-average assumptions used to determent of year benefit obligation	mine			2025		20	24				
Discount rate				5.75%		5.6	5%				
Rate of compensation increase				3.00%	3.00%						

For pension plans, actuarial gains for the year ended June 30, 2025 were the result of an increase in the discount rate, an update in near-term compensation and greater than assumed asset returns. Actuarial gains for the year ended June 30, 2024 were the result of an increase in the discount rate, offset by lower than assumed asset returns.

For postretirement plans, actuarial gains for the year ended June 30, 2025 and 2024 were the result from an increase in the discount rate, lower claims experience, higher than expected asset returns, and lower than expected participation; these are offset by a plan design amendment and an increase in healthcare cost trends.

The accumulated benefit obligations for the two pension plans at June 30, 2025 and 2024, were \$213.0 million and \$203.5 million, respectively.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

The University is currently pursuing enhancements to the postretirement health care benefits for certain employees and retirees. The University has announced an additional enhancement in the form of an increase in subsidies provided to certain employees and retirees to be effective January 1, 2026. This 2026 enhancement increased the plan's benefit obligation.

A 7.50 percent annual rate of increase in the per capita cost of covered health care benefits for the other postretirement benefit plan was assumed for 2026. The rate was assumed to decrease gradually to 4.75 percent for year ended June 30, 2037 and remain at that level thereafter. Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans.

Assets held by the pension plans and other postretirement benefit plan consist of investments in common collective trusts, which are valued at NAV as a practical expedient and are therefore excluded from the fair value hierarchy and reported as NAV.

The asset allocation for the pension plans at June 30, 2025 and 2024, and the target allocation for 2026, by asset category, follows:

	Target allocation	Percentage as sets at ye	-	
	2026 202			
Asset category				
U.S. large cap equity and global equity funds	19%	22%	22%	
International equities (non-U.S.)	9%	9%	9%	
High yield fixed income securities	7%	7%	7%	
U.S. fixed income	65%	62%	62%	
	100%	100%	100%	

The asset allocation for the other postretirement benefit plan at June 30, 2025 and 2024, and the target allocation for 2026, by asset category, follows:

	Target allocation	Percentage assets at year	•	
	2026	2025	2024	
Asset category				
U.S. large cap equity and global equity funds	31%	32%	32%	
International equities (non-U.S.)	12%	12%	12%	
U.S. fixed income	57%	56%	56%	
	100%	100%	100%	

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

### **Net Periodic Benefit Cost**

The components of net periodic benefit cost for pension benefits and other postretirement benefits are as follows:

	Pension Plan Benefits					Other Postretirement Benefits				
		2025		2024		2025	2024			
Components of net periodic benefit cost										
Service cost	\$	7,187	\$	7,109	\$	5,659	\$	5,090		
Interest cost on projected benefit obligation		12,711		11,859		7,543		6,581		
Expected return on assets		(12,807)		(12,735)		(13,780)		(14,041)		
Amortization of prior service cost						8,609		2,979		
Amortization of unrecognized net losses/(gain)						(6,375)		(4,721)		
Net periodic benefit cost	\$	7,091	\$	6,233	\$	1,656	\$	(4,112)		

# Amounts recognized in the Consolidated Statements of Activities

A summary of changes in plan assets and benefit obligations recognized in the consolidated statements of activities is as follows:

	]	Pension Plan Benefits			Other Postret Benefit				
		2025	2	2024		2025		2024	
Summary of changes in plan assets and benefit									
obligations recognized in the Consolidated									
Statements of Activities									
Net periodic benefit cost - service cost	\$	7,187	\$	7,109	\$	5,659	\$	5,090	
Total recognized in operating		7,187		7,109		5,659		5,090	
Net periodic benefit cost other than service cost		(96)		(876)		(4,003)		(9,202)	
Current year actuarial (gain)/loss		(2,309)		2,442	(	23,130)		(17,856)	
Amortization of actuarial gain/(loss)		, ,				6,375		4,720	
Current year prior service cost/(credit)						44,445		23,680	
Amortization of prior service cost						(8,609)		(2,979)	
Total recognized in nonoperating		(2,405)		1,566		15,078		(1,637)	
Total recognized in operating									
and nonoperating	\$	4,782	\$	8,675	\$	20,737	\$	3,453	
Weighted-average assumptions used to determine									
net periodic pension cost			2025			2024			
Discount rate			5.65%			5.40%		ī	
Expected return on plan assets			5.50%			5.50%			
-			3.00%			3.00%			
Rate of compensation increase			3.00%	ט		3.0070			

To arrive at assumptions for expected long-term rates of return on assets in the pension plans and the postretirement benefit plan, the University considered historical returns and future expectations for returns in each asset class in the asset allocation for the previously described pension and postretirement benefit portfolios.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# **Expected Cash Flows**

Information about the expected cash flows for the plans is as follows:

	 ension Plan Benefits	 Postretirement Benefits		
<b>Expected University contributions</b>	 			
2026	\$ 7,091			
Expected benefit payments				
2026	\$ 11,240	\$ 7,095		
2027	11,864	7,567		
2028	12,533	8,010		
2029	13,063	8,460		
2030	13,729	9,041		
2031-2035	78,002	54,796		
Total	\$ 140,431	\$ 94,969		

Total benefits expected to be paid include the University's share of the benefit cost net of Medicare subsidies and the participants' share of the cost, which is funded by participant contributions to the other postretirement benefit plan. The University receives a Medicare Part D subsidy from the federal government as reimbursement for certain retiree health benefits paid to plan participants, which was approximately \$0.1 million in fiscal year 2025.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 13. Lease Obligations

The University is the lessee of various equipment and space under noncancelable right of use and finance leases. Finance lease obligations at June 30, 2025 and 2024, were \$134.9 million and \$131.2 million, respectively. Right of use lease obligations at June 30, 2025 and 2024 were \$271.2 million and \$266.3 million, respectively.

Rental expense related to operating leases totaled \$39.7 million and \$38.8 million for fiscal years ended 2025 and 2024, respectively. Future minimum rental payments under right of use and finance leases are as follows:

Finance

Dight of use

	K	_ Right of use_		r inance
Future minimum rental payments:				_
2026	\$	37,147	\$	11,764
2027		36,539		10,197
2028		33,483		8,867
2029		33,177		7,684
2030		30,981		7,436
Thereafter		164,961		198,852
Total lease payments		336,288		244,800
Less: Imputed Interest		(65,057)		(109,890)
Present value of lease obligations at June 30, 2025	\$	271,231	\$	134,910

Weighted-average remaining lease term and discount rate for right of use and finance leases are as follows:

_	2025	2024
Weighted average remaining lease term (in years)		
Right of use leases	6.3	6.3
Finance leases	15.3	16.2
Weighted average discount rate		
Right of use leases	3.96%	3.75%
Finance leases	4.34%	4.52%

Cash paid for amounts included in the measurement of lease obligations is presented in the Statements of Cash Flows as follows:

		2025	2024		
Operating cash flows for right of use leases	\$	(39,219)	\$	(39,623)	
Operating cash flows for finance leases	\$	5,982	\$	5,799	
Financing cash flows for finance leases	\$	(13,107)	\$	(11,849)	

The University leases properties to customers under agreements that are classified as right of use leases. The University's lessor arrangements are all operating leases and do not include any salestype or direct finance leases. Space and equipment leased to others are included in "Land, buildings, and equipment, net" and "Institutional real estate" in the consolidated statements of financial position.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024 (in thousands of dollars, unless otherwise noted)

# 14. Conditional Asset Retirement Obligations

Conditional asset retirement obligations are a legal obligation to perform an asset retirement activity in which the timing and/or method of settlement are conditioned on a future event that may or may not be within the control of the University. The University recognizes the fair value of this obligation in the period in which it occurred if a reasonable estimate of fair value can be made. Uncertainty with respect to the timing and/or method of settlement of the asset retirement obligation does not defer recognition of a liability.

Conditional asset retirement obligations related to remediation or disposal of asbestos, underground storage tanks, soil, radioactive sources, equipment, and miscellaneous other items were \$144.8 million and \$138.6 million at June 30, 2025 and 2024, respectively.

Notes to the Consolidated Financial Statements

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 15. Bonds and Notes Payable

Bonds and notes payable outstanding are as follows at June 30:

Bonds and notes payable outstanding are as follows at rune 50.		2025		2024
Dormitory Authority of the State of New York, tax exempt		2023		2024
revenue bonds, Columbia University issues:				
Series 2024 A, 2.38% to 2.69%, maturing FY2032 to FY2037	\$	150,000		
Series 2023 A, 2.59% to 2.68%, maturing FY2033 to FY2035	Ψ	275,000	\$	275,000
Series 2020 A, 2.11%, maturing FY2051		150,000	Ф	150,000
		150,000		150,000
Series 2018 A, 2.45% to 3.41%, maturing FY2029 to FY2049		· · · · · · · · · · · · · · · · · · ·		,
Series 2018 B, 2.98%, maturing FY2039		175,185		175,185
Series 2017 A, 2.40% to 3.49%, maturing FY2028 to FY2048		150,000		150,000
Series 2017 B, 2.14% to 2.61%, maturing FY2026 to FY2030		37,235		40,475
Series 2016 A-1, 1.67%, maturing FY2027		50,000		50,000
Series 2016 A-2, 1.91% to 2.89%, maturing FY2026 to FY2047		111,135		120,955
Series 2016 B, 1.55% to 2.04%, maturing FY2026 to FY2032		76,055		85,015
Series 2015 A, 1.95% to 3.00%, maturing FY2026 to FY2046		92,535		92,535
Series 2015 B, 1.88%, maturing FY2025				2,580
Series 2009 A, variable rate, 1.75%, maturing FY2039		117,000		117,000
Series 2003 B, variable rate, 1.82%, maturing FY2026 to FY2028		22,090		28,915
Series 2002 C, variable rates, 2.77% to 3.50%, maturing FY2026 to FY2027		15,910		23,300
Taxable Series 2024 B, 4.36%, maturing FY2035 to FY2036		350,000		
Taxable Series 2021 A, 2.85%, maturing FY2051		125,000		125,000
Taxable Series 2021 B, 1.52% to 2.59%, maturing FY2031 to FY2050		180,000		180,000
Taxable Series 2020 B, 2.34%, maturing FY2026 to FY2030		25,000		50,000
Taxable Series 2015, 3.46%, maturing FY2046		75,000		75,000
Taxable Series 2012, 3.83%, maturing FY2043		100,000		100,000
New Jersey Economic Development Corporation, tax exempt				
Series 2002, variable rate, 3.00%, maturing FY2028		1,695		2,230
Empire State Development Corporation issues:				
9.00%, maturing FY2029		2,601		3,238
Tax-Exempt Commercial Paper, variable rate, 2.80% to 2.94%		105,000		
Subtotal, principal payments		2,536,441		1,996,428
Unamortized bond premium		255,396		256,984
Unamortized cost of issuance		(5,067)		(3,848)
Subtotal, bond premium and cost of issuance		250,329		253,136
Total bonds and notes payable	\$	2,786,770	\$	2,249,564

# **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

Estimated principal payments on bonds and notes payable are summarized below:

Fiscal Year	<b>Principal</b>
2026	\$ 71,625
2027	84,228
2028	52,101
2029	67,448
2030	50,805
Thereafter (through 2051)	2,105,234
Subtotal, Bonds and Notes Payable	\$ 2,431,441
Tax-exempt Commercial Paper	105,000
Total, Principal Payments	\$ 2,536,441

The University issues most of its tax-exempt debt through the Dormitory Authority of the State of New York ("DASNY"). In October 2024, the University issued \$150 million of Series 2024A, tax-exempt fixed rate bonds, and \$350 million of Series 2024B, taxable fixed rate bonds. Series 2024A was issued at a premium of \$27.6 million which will be amortized over seven to twelve years based on the maturity of underlying bonds. The proceeds from Series 2024A were used to finance various construction and renovation projects. The proceeds from Series 2024B were used for general corporate purposes.

The University has a \$150 million taxable commercial paper program. There was no taxable commercial paper outstanding under this program as of June 30, 2025 and 2024, respectively.

The University established a \$200 million tax-exempt commercial paper program in November 2024. There was \$105 million of tax-exempt commercial paper outstanding under this program as of June 30, 2025.

The University recorded amortization of bond premium and issuance costs, net, of \$29.2 million and \$28.0 million for the years ended June 30, 2025 and 2024, respectively, as a reduction to interest expense.

As of June 30, 2025, the University had the following operating lines of credit: \$150 million expiring in May 2028; \$100 million expiring in November 2026; \$100 million expiring in April 2026; \$200 million expiring in October 2025. Additionally, the University had two \$100 million standby lines of credit supporting self-liquidity for variable rate debt outstanding. Both lines expire in January 2028. The lines are provided by five different lending institutions, and as of June 30, 2025, no balances were outstanding on the lines of credit. In September 2025, the University renewed the \$200 million operating line of credit, originally set to expire in October 2025, through October 2028.

The University has administrative covenants on its tax-exempt debt and lines of credit, with which it was in compliance as of June 30, 2025 and 2024.

In October, 2008, the University entered into a \$200 million notional value fixed payer interest rate swap agreement, expiring in April 2038, to protect against the risk of interest rate changes. The estimated fair value of the swap liability was \$24.6 million and \$23.8 million at June 30, 2025 and

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024 (in thousands of dollars, unless otherwise noted)

2024, respectively. The fair value of the swap is obtained by taking the present value of all future cash flows on the swap implied by the forward curve.

The University has letters of credit with various financial institutions totaling \$78.2 million and \$78.5 million at June 30, 2025 and 2024, respectively, primarily to secure certain self-insured liabilities in accordance with New York State requirements related to workers' compensation. There have been no draws under the letters of credit.

### 16. Insurance

In connection with managing financial risks through various third-party insurance programs, the University is self-insured in certain areas. Funded self-insurance liabilities primarily cover deductibles on general liability, trustees and officers' liability, and property insurance claims. Self-insurance liabilities are actuarially calculated on a semi-annual basis. The University's core liability coverage is purchased through Pinnacle RRG, a Vermont-based risk retention group with seventeen other universities.

The University obtains medical malpractice insurance through MCIC and MLMIC. MCIC is a group-captive insurance company owned by the University, The Johns Hopkins Hospital, The Johns Hopkins University, University of Rochester Medical Center, Weill Cornell Medical College, Yale New Haven Health, Yale University School of Medicine, and NYP. MLMIC is a mutual company where policyholders are owners with full voting rights to elect the company's Board of Directors, thereby having direct input into vital areas of operation. The governing Board is comprised primarily of practicing physicians, dentists, and hospital administrators. More than 2,200 of the University's faculty physicians and dentists are enrolled in MCIC or MLMIC. The University has recorded self-insurance and medical malpractice liabilities of approximately \$404.0 million and \$377.9 million as of June 30, 2025 and 2024, respectively; amounts are reported in both "Other long-term liabilities" and "Accrued employee benefit liabilities" in the consolidated statements of financial position. The medical malpractice liabilities of approximately \$234.1 million and \$225.8 million as of June 30, 2025 and 2024, respectively, are reported gross with an offsetting receivable for anticipated recoveries of \$158.2 million and \$152.7 million, respectively, recorded in "Other assets" in the consolidated statements of financial position.

# The Trustees of Columbia University in the City of New York **Notes to the Consolidated Financial Statements**

For the Years Ended June 30, 2025 and 2024 (in thousands of dollars, unless otherwise noted)

### 17. **Affiliations and Related Party Transactions**

The University maintains several clinical and education affiliation agreements with other organizations. Revenues and expenses from these agreements are accounted for in the operating activities section of the consolidated statements of activities. The most significant affiliation agreement is with NYP.

The University receives reimbursement from NYP for the provision of medical, professional, and supervisory staff services as well as other technical assistance. NYP provides funding to clinical departments for specific purposes including administration, supervision, and teaching of the NYP resident staff and salary support for faculty and staff providing services to NYP. In addition, NYP provides funding for clinical programs that the University and NYP would like to see developed or expanded. NYP also provides the departments with certain facilities and services (outpatient faculty practice offices, nursing, telecommunications, etc.) for which the University is invoiced on a monthly basis. Finally, the University and NYP collaborate and fund joint projects for which specific agreements are negotiated.

In addition, the University and NYP negotiate a funds flow, which forms the basis for the affiliation agreement. The fiscal year 2025 revenue recorded from this funds flow was approximately \$463.5 million. The payments to NYP for goods and services were \$135.6 million and \$119.1 million for the years ended June 30, 2025 and 2024, respectively. The majority of revenues received pursuant to this agreement are reflected in the consolidated statements of activities as a portion of "Patient care revenue" and the majority of the expenses related to this agreement are reflected in "Patient care expense".

The University records both receivables from and payables to NYP on the consolidated statements of financial position. The University has no liability for obligations and debt incurred by NYP. The University and NYP operate a radiological imaging center, ColumbiaDoctors/NewYork-Presbyterian Imaging, Inc. (CDNYPI). CDNYPI is a not-for-profit membership corporation, which was incorporated to operate pursuant to the terms and provisions of Article 28 of the New York Public Health Law, whereby it provides a full range of general radiology and interventional radiology services. In order to provide for efficient delivery of services and to secure a high level of expertise from existing resources, CDNYPI has entered into clinical and administrative agreements with the University and NYP. The revenue generated from these agreements was \$55.2 million and \$44.6 million for the years ended June 30, 2025 and 2024, respectively. The University recorded an interest in CDNYPI in the amount of \$33.7 million and \$38.1 million as of June 30, 2025 and 2024, respectively, in "Other assets" in the consolidated statements of financial position. The University's interest in CDNYPI reflected a \$10.0 million distribution from CDNYPI for the year ended June 30, 2025.

Subsequent to fiscal year end, the University and NYP formed a second radiological imaging center, Columbia/NewYork-Presbyterian Advance Imaging, Inc. (CNYPAI), which went-live on July 1, 2025. CNYPAI is a not-for-profit membership corporation, which was incorporated to operate pursuant to the terms and provisions of Article 28 of the New York Public Health Law, whereby it provides full range of general radiology services.

From time to time endowment funds held for the benefit of the University may be transferred from the CPMC Fund, Inc. to the University pursuant to the consent of the Trustees of the CPMC Fund, Inc. There were no transfers during the years ended June 30, 2025 and 2024.

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 18. Liquidity and Availability of Resources

As part of the University's liquidity management, financial assets are structured to be available as its general expenditures, liabilities, and other obligations come due. In addition, the University may invest cash in excess of daily requirements in short-term and/or liquid investments. To further help manage unanticipated liquidity needs, the University has committed bank lines of credit along with a taxable commercial paper program.

The University's financial assets and liquidity resources available for general expenditures within one year of the date of the consolidated statements of financial position are as follows:

	2025			
Financial Assets:				
Cash and cash equivalents	\$	1,145,338	\$	974,557
Accounts receivable, net		980,529		721,627
Pledges receivable for operations and plant, net		141,963		104,363
Operating investments		931,738		1,365,885
Approved endowment payout for subsequent year		736,140		661,438
Other financial assets		615		589
Total financial assets available within one year		3,936,323		3,828,459
Liquidity resources:				
Taxable commercial paper program, net		150,000		150,000
Tax-exempt commercial paper program, net		95,000		
Bank lines of credit (undrawn)		750,000		750,000
Total liquidity resources available		995,000		900,000
Total financial assets and liquidity resources				
available within one year	\$	4,931,323	\$	4,728,459

Additionally, the University has board-designated funds functioning as endowments of \$4.6 billion and \$4.3 billion as of June 30, 2025 and 2024, respectively. Although the University does not intend to spend from these endowments beyond the amounts appropriated for general expenditure as part of its annual appropriation process, \$4.1 billion and \$3.8 billion, respectively, is without donor restrictions and could be made available if necessary as of June 30, 2025 and 2024. However, both the funds functioning as endowment and donor-restricted endowments contain investments with lock-up provisions that reduce the total investments that could be made available (see Note 5 for disclosures about investments).

**Notes to the Consolidated Financial Statements** 

For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 19. Contingencies and Commitments

From time to time, various claims and suits generally incident to the conduct of normal business are pending or may arise against the University.

In the opinion of counsel and management of the University, after taking into account insurance coverage, losses, if any, from the resolution of pending legal matters, including malpractice claims, should not have a material adverse effect on the University's operations or financial condition.

The University and NYP have settled malpractice claims involving alleged sexual misconduct by a formerly-employed physician. The University has accrued for associated losses in the consolidated financial statements. Management believes all material amounts in connection with this matter have been recognized and paid as of June 30, 2025.

All funds expended in connection with government grants and contracts are subject to audit by government agencies. While the ultimate liability, if any, from audits of government grants and contracts by government agencies, claims, and suits is presently not determinable, it should not, in the opinion of counsel and management, have a material effect on the University's financial position or results of activities.

In July 2025, the University entered into a three-year agreement with the United States Government in settlement of certain regulatory inquiries. Under this agreement, the University commits to a set of institutional actions and the government agrees to take certain actions with respect to the University's federal grants and contracts. The full settlement amount is recorded in the consolidated statement of activities for the year ending June 30, 2025, and will be paid over the course of the three-year agreement.

The University is subject to laws and regulations concerning environmental remediation and will, from time to time, establish reserves for potential obligations that management considers probable and for which reasonable estimates can be made (see Note 14 for disclosures about conditional asset retirement obligations). These estimates may change depending upon the nature and extent of contamination, appropriate remediation technologies, and regulatory approvals. The University is not aware of any existing conditions that it currently believes are likely to have a material adverse effect on the University's financial position, changes in net assets, or cash flows.

The University's capital improvement program and related commitments include projects that address the major strategic objectives of the University. As part of the capital improvement program, the University has entered into contracts to purchase properties with an aggregate value of \$173.5 million. As of June 30, 2025, approximately \$163.5 million is still outstanding.

The University has made commitments related to its expansion in Manhattanville, certain of which are based upon events in the future which would result in cash and in-kind payments from the University. Those that are probable and estimable have been recorded as liabilities.

# The Trustees of Columbia University in the City of New York Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024

(in thousands of dollars, unless otherwise noted)

# 20. Expenses by Functional and Natural Classification

Expenses are reported for the University's primary program activities. The consolidated statements of activities also report certain categories of expenditures that support more than one major program of the University. These expenses include operation and maintenance of plant, depreciation expense, and interest expense.

Expenses by functional and natural classification, which include operating expenses and exclude nonoperating expenses, for the years ended June 30, 2025 and 2024 are as follows:

	•					2025					
						Natural	Classi	fication post A	llocat	ion	
	St	Expenses per Statement of Activities		Allocation		mpensation nd Benefits		Other		Final Allocated Expenses	
Instruction and educational administration	e	2 462 000	¢	260.456	e	2.020.546	¢	001.010	e	2 922 256	
	\$	2,462,900	\$	369,456	\$	2,030,546	\$	801,810	\$	2,832,356	
Research		988,703		137,588		564,207		562,084		1,126,291	
Patient care expense		1,682,558		92,010		1,427,219		347,349		1,774,568	
Operation and maintenance of plant		404,668		(404,668)		260 404		240.760			
Institutional support		459,343		59,907		269,481		249,769		519,250	
Auxiliary enterprise		232,272		147,643		146,649		233,266		379,915	
Depreciation expense		322,573		(322,573)							
Interest expense	_	79,363		(79,363)	_		_		_		
Total operating expenses	\$	6,632,380			\$	4,438,102	\$	2,194,278	\$	6,632,380	
					2024						
					Natural Classification post Allocation						
		xpenses per atement of			Co	mpensation				Final Allocated	
		Activities	Α	Illocation	aı	nd Benefits		Other		Expenses	
Instruction and educational administration	\$	2,415,561	\$	346,970	\$	1,945,744	\$	816,787	s	2,762,531	
Research		951,340	-	129,249	*	559,438	*	521,151		1,080,589	
Patient care expense		1,555,432		90,810		1,306,090		340,152		1,646,242	
Operation and maintenance of plant		367,001		(367,001)		, ,		, -		,,	
Institutional support		386,280		56,551		252,086		190,745		442,831	
Auxiliary enterprise		228,339		138,381		137,920		228,800		366,720	
Depreciation expense		327,635		(327,635)		/,>20		0,000		2 30,720	
Interest expense		67,325		(67,325)							
Total operating expenses	\$	6,298,913		(07,020)		4,201,278	\$	2,097,635	\$	6,298,913	

The allocation of operation and maintenance of plant is based on square footage occupancy. Depreciation expense includes depreciation of buildings, building improvements, and equipment. The allocation of depreciation on buildings and building improvements is based on square footage occupancy. Depreciation on equipment is allocated to the programs for which the equipment was purchased. Interest expense is allocated according to the same methodologies used for building depreciation.

Notes to the Consolidated Financial Statements For the Years Ended June 30, 2025 and 2024 (in thousands of dollars, unless otherwise noted)

# 21. Subsequent Events

The University has performed an evaluation of subsequent events through October 23, 2025, which is the date the consolidated financial statements were issued.